Skip to Content
Merck
  • The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.

The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.

Bioorganic & medicinal chemistry letters (2006-02-04)
Nicholas Stock, Benito Munoz, Jonathan D J Wrigley, Mark S Shearman, Dirk Beher, James Peachey, Toni L Williamson, Gretchen Bain, Weichao Chen, Xiaohui Jiang, René St-Jacques, Peppi Prasit
ABSTRACT

The subtle modification of a selection of Abeta42 inhibiting non-steroidal anti-inflammatory drugs (NSAIDs), through synthesis of the geminal dimethyl analogues, was anticipated to ablate their cyclooxygenase activity whilst maintaining Abeta42 inhibition. Methylflurbiprofen 6 exhibited similar in vitro Abeta42 inhibition to its parent NSAID Flurbiprofen and was further evaluated in the Tg2576 mouse model of Alzheimer's disease and an animal model of gastro-intestinal (GI) impairment, but proved unviable for further clinical development.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Supelco
Ibuprofen
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Sigma-Aldrich
Mefenamic acid
Supelco
Naproxen, VETRANAL®, analytical standard
Sigma-Aldrich
Naproxen, meets USP testing specifications
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
Acetaminophen, analytical standard
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%